Biogen CEO says encouraged by strength of Spinraza launch
"Our multiple sclerosis portfolio demonstrated resilience in an increasingly competitive market, and we're encouraged by the strength of SPINRAZA's global launch. We had a solid third quarter, and over the balance of the year we anticipate seasonal pressure as well as increased spending as we invest behind our strategic priorities. We believe that our new agreements with Eisai and Neurimmune will improve our long-term economics of aducanumab. We are pleased by Eisai's decision to exercise their option on aducanumab, demonstrating their confidence in the asset. The region-based profit split with Eisai is designed to leverage each company's respective geographic strengths and infrastructures. We made important progress advancing our pipeline, including initiating new trials in Alzheimer's disease and epilepsy and completing enrollment of studies in stroke and Parkinson's disease. In the next 12 months, we expect data readouts from multiple programs across our core and emerging growth areas," said Biogen's CEO Michel Vounatsos.